Welcome to our dedicated page for Movano news (Ticker: MOVE), a resource for investors and traders seeking the latest updates and insights on Movano stock.
Movano Inc. (Nasdaq: MOVE), doing business as Movano Health, generates news at the intersection of wearable medical devices, health technology, and corporate transformation. Founded in 2018, the company develops devices such as the Evie and EvieMED rings, which are designed to bring medical-grade data into consumer and enterprise wearables. Its disclosures highlight capabilities that span physiological monitoring, women’s wellness, and proprietary RF-based sensing for cuffless blood pressure and noninvasive glucose monitoring.
News coverage of Movano frequently includes product and technology updates. The company has announced clinical study results for its wrist-worn cuffless blood pressure prototype, noting accuracy within standards recognized by the FDA for wearable, cuffless blood pressure devices and the ability to collect additional vital signs such as pulse rate, SpO2, respiration rate and ECG waveforms. It has also reported enhancements to the Evie Ring’s companion app, including new personalization and trend-tracking features, integration with Apple Health, expanded workout logging, and the introduction of EvieAI, a virtual wellness assistant built from medical journal data.
Movano’s news flow also reflects regulatory and listing developments. The company has issued multiple press releases regarding Nasdaq notifications related to bid price, periodic filing timeliness, and stockholders’ equity requirements, as well as its responses, such as engaging a new independent auditor, submitting compliance plans, and implementing a one-for-ten reverse stock split to support bid price compliance. Investors following MOVE news can track how these steps affect the company’s continued listing on the Nasdaq Capital Market.
A significant portion of recent headlines centers on strategic and transactional events. Movano’s board initiated a process to explore strategic alternatives, including a sale or merger, to maximize shareholder value. This process led to a definitive Agreement and Plan of Merger with Corvex, Inc., an AI cloud computing company specializing in GPU-accelerated infrastructure. Related announcements describe the planned all-stock combination, ownership structure expectations, concurrent financings, and the intention to rename Movano Inc. as Corvex, Inc. upon closing, with the combined company headquartered in Arlington, Virginia. Movano has also communicated that it may market for sale its current operating assets, including the EvieMED Ring and its mmWave RF technology, prior to completion of the merger.
By monitoring the MOVE news feed, readers can follow updates on Movano’s wearable health products, clinical and regulatory milestones, listing status, financing activities, and the progress of its proposed merger with Corvex. This stream of information helps investors and observers understand both the company’s health technology initiatives and its potential evolution into a public vehicle for AI infrastructure through the planned combination.
Movano has joined the American Heart Association's Innovators' Network, aiming to advance health tech solutions. This consortium connects healthcare entrepreneurs, researchers, and payers to foster innovative healthcare technology. Movano's initiative focuses on enhancing health outcomes for chronic conditions like hypertension and diabetes through its Movano Ring. The partnership allows access to the Association's digital guidelines and research, promoting clinical studies and improving healthcare outcomes.
Movano Inc. (NASDAQ:MOVE) has announced its plan to report first quarter 2022 financial and operating results on May 12, 2022. The company will host a conference call at 2 p.m. PDT to discuss these results and provide a business update. Interested parties can access the live webcast on Movano's investor website. Founded in 2018, Movano aims to deliver healthcare solutions that combine health data with personalized feedback, aiding in chronic condition management.
Movano Inc. (NASDAQ: MOVE) announced the appointment of Tyla Bucher as Chief Marketing Officer to enhance its marketing strategy for the upcoming Movano Ring and future products. Bucher, with over two decades of experience in global marketing, previously drove significant brand awareness and revenue growth at Hydrow and Hasbro. The Movano Ring, designed specifically for women, aims to provide vital health metrics and will beta test in late 2022. Additionally, the company reserved 2 million shares for equity awards to enhance recruitment efforts.
Movano Inc. (Nasdaq: MOVE) announced the addition of Nan Kirsten Forte to its board of directors on April 18, 2022. Forte brings over 30 years of experience in healthcare media, having held key positions at WebMD and Everyday Health. Her expertise spans marketing, product innovation, and strategic partnerships, which aligns with Movano's mission to empower women's health solutions. Movano is gearing up for growth with its flagship product, the Movano Ring, designed to provide vital health metrics, set for beta release in late 2022.
Movano Inc. (NASDAQ: MOVE) announced its fourth quarter 2021 financial results, reporting a net loss of $6.3 million, or $0.19 per share, an improvement from a $7.4 million loss in Q4 2020. The total 2021 net loss was $24.3 million. The company, focused on women's health, introduced the Movano Ring, a smart ring set for Beta launch in H2 2022, following successful clinical studies on blood pressure and glucose. Movano had $33.6 million in cash as of December 31, 2021, significantly up from $5.7 million in 2020, indicating strong financial backing for its R&D efforts.
Movano Inc. (NASDAQ:MOVE) announced it will report its fourth quarter 2021 financial and operating results on March 24, 2022. The management team will host a conference call and live audio webcast at 2:00 p.m. PDT to discuss these results, providing an update on business operations. The webcast can be accessed via Movano's investor website, and an archived version will be available afterward. Movano focuses on developing health technologies aimed at delivering vital health information to enhance individual well-being.
Movano Inc. (NASDAQ:MOVE) announced the completion of its second glucose pilot study, involving 10 participants with type 1 diabetes. The study, approved by the Institutional Review Board, tested Movano's wrist-worn prototype against FDA-cleared devices to refine its algorithms for glucose and vital sign measurements. CEO Dr. John Mastrototaro emphasized the aim to create stylish, affordable, FDA-cleared devices for monitoring chronic conditions. The study's results will inform future clinical trials and regulatory approvals, enhancing Movano's technology for managing diabetes and hypertension.
Movano Inc. (Nasdaq: MOVE) announced the addition of Stacy Salvi as Vice President of Strategy and Michael Soule as Vice President of Business Development. These strategic hires aim to enhance the company's go-to-market strategy for the upcoming Movano Ring, designed to provide vital health insights. The company has reserved 2,000,000 shares for equity awards to attract talent. Recently, 720,000 stock options were granted to nine new non-executive employees, enhancing Movano's operational capacity and growth potential.
Movano Inc. (Nasdaq: MOVE), a health technology company, announced its participation in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 15 to February 17, 2022. CEO John Mastrototaro will present the company’s debut device, the Movano Ring, which was showcased at CES 2022. Founded in 2018, Movano focuses on creating personalized health devices that provide vital health data, including glucose and blood pressure. For further details, visit movano.com.
Movano Inc. (Nasdaq: MOVE) announced the award of three new U.S. patents, bringing its total to six. The patents focus on non-invasive sensor technology that combines Radio Frequency (RF) and mmWave capabilities into a single Integrated Circuit (IC) for future wearable devices. With over 40 pending applications, the company aims to provide health metrics like glucose and blood pressure. CEO John Mastrototaro emphasized that these innovations will enhance data accuracy and differentiate Movano’s products in the market.